Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

In June 2026, 10,000 of the 19th Stock Acquisition Rights were exercised, and 1,000,000 shares were delivered. The number of unexercised Stock Acquisition Rights at month-end was 230,000.

Worth reading
63In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1000000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)

発行・処分する株式数

Shares delivered during the month: 1,000,000 new shares and 0 treasury shares transferred. Stock Acquisition Rights exercised during the month: 10,000

Intended allottee
EVO FUND (the intended allottee at issuance)
発行済株式総数

Exercise ratio subject to exercise restrictions: 1.0% (1,000,000 shares delivered / 96,334,098 listed shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥30.0–¥35.0. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 240,000; unexercised as of 12 June 2026: 240,000; unexercised as of the end of June 2026: 230,000
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
12 June 2026: Issuance of the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount: Not disclosed, 12 June 2026: Issuance of the 2nd Unsecured Corporate Bonds (private placement). Amount: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)
Number of shares to be issued or disposed ofShares delivered during the month: 1,000,000 new shares and 0 treasury shares transferred. Stock Acquisition Rights exercised during the month: 10,000
Intended allotteeEVO FUND (the intended allottee at issuance)
Dilution RateExercise ratio subject to exercise restrictions: 1.0% (1,000,000 shares delivered / 96,334,098 listed shares)
Total number of issued sharesAs of 12 June 2026: 96,334,098 shares → Not disclosed
Exercise priceExercise price during the month: ¥30.0–¥35.0. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 240,000; unexercised as of 12 June 2026: 240,000; unexercised as of the end of June 2026: 230,000
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing12 June 2026: Issuance of the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount: Not disclosed, 12 June 2026: Issuance of the 2nd Unsecured Corporate Bonds (private placement). Amount: Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status. No other reason is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori